Stockscreener 앱 받기
3.69
1.34%
-0.05
시간 외 거래:
3.58
-0.11
-2.98%
전일 마감가:
$3.74
열려 있는:
$3.78
하루 거래량:
1.03M
Relative Volume:
1.79
시가총액:
$166.88M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-4.10
EPS:
-0.9
순현금흐름:
$-31.47M
1주 성능:
+18.27%
1개월 성능:
+41.92%
6개월 성능:
+4.83%
1년 성능:
+232.43%
1일 변동 폭
$3.50
$3.8184
1주일 범위
$3.00
$3.8184
52주 변동 폭
$0.94
$6.42
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Cardiff Oncology (FRA:XE7C) Float Percentage Of Total Shares Outstanding : 97.27% (As of Nov. 02, 2024) - GuruFocus.com
Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Up 7.2% in October - MarketBeat
Cardiff Oncology Announces Journal of Clinical Oncology - GlobeNewswire
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC - StockTitan
Alley Investment Management Company LLC Purchases New Stake in NVIDIA Co. (NASDAQ:NVDA) - Defense World
NA Liquid Biopsy Market 2024 To Witness Amazing Growth By 2032 - openPR
3 US Penny Stocks With Market Caps Over $40M - Simply Wall St
JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the Domain - The Malaysian Reserve
KRAS Inhibitors Market Poised to Reach $157.6 Million by 2031, Driven by 5.61% CAGR As Revealed In New Report - WhaTech
Will Cardiff Oncology's Onvansertib Data Boost Its Stock Price? - RTTNews
Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Cardiff Oncology Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Cardiff Oncology Inc (CRDF) Q2 2024 Earnings Call Highlights: Strategic Trials and Financial ... - Yahoo Finance
Neuroendocrine Tumors Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate - Simply Wall St
Its Stock Has Paid Off Big Time For Cardiff Oncology Inc - SETE News
Stock Performance Spotlight: Cardiff Oncology Inc (CRDF) Ends the Day at 2.60, Up by 2.77 - The Dwinnex
CRDF (Cardiff Oncology Inc) has impressive results - US Post News
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market - Seeking Alpha
Take off with Cardiff Oncology Inc (CRDF): Get ready for trading - SETE News
Market Insight: Cardiff Oncology Inc (CRDF)’s Notable Drop, Closing at 2.47 - The Dwinnex
How to interpret Cardiff Oncology Inc (CRDF)’s stock chart patterns - US Post News
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - The Malaysian Reserve
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sunbelt Securities Inc. - Defense World
KRAS Inhibitors Market: New Treatments Are Set to Change Cancer Care | DelveInsight - 新浪香港
IGC Pharma, Inc. (NYSEMKT:IGC) Director Buys $199,999.90 in Stock - Defense World
Blair William & Co. IL Raises Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Delta Investment Management LLC Cuts Stock Position in JPMorgan Ultra-Short Income ETF (NYSEARCA:JPST) - Defense World
Cardiff City . . . The Doom Loop Club Stuck On Groundhog Day - Dai Sport
Investment Opportunities: Capitalizing on the Global Kras - openPR
Cardiff City need 'long-term strategy' after Erol Bulut exitRob Earnshaw - BBC.com
Tonight's Cardiff City news as 'stunned' club release statement and pundit picks 'fantastic' fit for job - Yahoo News UK
Trading Day Review: Cardiff Oncology Inc (CRDF) Loses Momentum, Closing at 2.58 - The Dwinnex
Pompey Championship rival moves quickly to sort managerial mess after weekend sacking - Portsmouth News
Cardiff going from 'one crisis to another' - Yahoo Sport Australia
Next Cardiff City manager odds latest as Wales legend gatecrashes race - Yahoo News UK
The surprise Welsh names leading the field to become new Cardiff City manager - Nation.Cymru
Blackburn Rovers' rivals confirm third managerial casualty in the Championship - Lancashire Telegraph
Cardiff City candidate 'would love' to manage club after already rescuing Vincent Tan - Wales Online
Bluebirds give Bulut the bullet - MSN
Next Cardiff manager odds: Erol Bulut sacked after poor start - Sportinglife.com
SACKED! Cardiff axe Bulut - Tribal Football
Cardiff City sack Erol Bulut as club seek new manager - Wales Online
Next Cardiff Manager Odds: Who is favourite to replace Erol Bulut? - Oddschecker
Middlesbrough and Sunderland rivals looking for new boss after swift sacking call - Yahoo Eurosport UK
Cardiff City fire manager Erol Bulut - BBC
Cardiff Capital Region invests £45m in Ogi to boost digital connectivity - South Wales Argus
Market Watch Highlights: Cardiff Oncology Inc (CRDF) Ends on an Upturn Note at 2.53 - The Dwinnex
Cardiff Oncology Inc (CRDF)’s results reveal risk - US Post News
Tonight's Cardiff City news as Aaron Ramsey faces months out and Erol Bulut hits out over rumour - Wales Online
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):